

Washington University COVID-19 Response

William Powderly, MD

Christina Gurnett, MD, PhD

Director and Associate Director, ICTS

AIM

Facilitate a cohesive pandemic response strategy across the university

INITIATIVES

- Prioritization of COVID-19 clinical research
- Creation of a biorepository
- Integration of large-scale patient data from multiple sources
- Solicit feedback from community members

SUMMARY

- ICTS' flexible structure allows for a rapid, nimble, multi-faceted response
- Lessons learned can be applied to future health crises
- Collaborations with partner institutions and community stakeholders are crucial

VISIT

<https://icts.wustl.edu/covid-19>



WASHINGTON UNIVERSITY IN ST. LOUIS
Institute of **C**linical and **T**ranslational **S**ciences

CTSA Hubs are uniquely positioned to lead the response to a national health crisis such as COVID-19.



CONTACT

Christina Buckel, MSW
buckelcm@wustl.edu



HIGHLIGHTS

- Multi-disciplinary effort to develop and obtain FDA approval for COVID-19 saliva test
- ICTS Director, William Powderly, serves as protocol chair for national ACTIV-1 Immune Modulators trial
- Biorepository distributed 15,655 samples from 672 participants to more than 20 investigators
- Community Advisory Board consulted on recruitment of underrepresented minorities for vaccine research, testing in schools for vulnerable populations, genetic conditions revealed during COVID-19 research
- Awarded pilot funding to 11 COVID-19 projects
- Phase III vaccine trials at Washington University and partner institution Saint Louis University
- 200 COVID-19 research projects submitted to the ICTS portal for basic, clinical and data research